Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -
Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Friday, June 15, 2012
- Balance problems
- Lack of coordination
How Do I Find a Physical Therapist?
How Many Visits Will I Need to Get Relief?
Teva Announces Top-Line Results from GALA Phase III Trial Evaluating a New Dosage for Glatiramer Acetate Given Three Times Weekly for Relapsing-Remitting Multiple Sclerosis
Wednesday, June 13, 2012
Read more: http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=59968#ixzz1xh9qoRzl
Tuesday, June 12, 2012
Monday, June 11, 2012
6/11/2012 2:14 AM ET
(RTTNews) - Swiss drugmaker Novartis AG (NVS: News ) on Monday said a new data for multiple sclerosis drug Gilenya (fingolimod) showed long-term efficacy benefit and a consistent profile.
Gilenya, licensed from Japan's Mitsubishi Tanabe Pharma Corp., is the only oral therapy approved to treat people with relapsing forms of multiple sclerosis.
The data from single-arm extension of phase III head-to-head TRANSFORMS study showed sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment for up to 4.5 years, the noted
The results also showed improved efficacy for patients switched to Gilenya from Avonex (interferon-beta-1a IM), a commonly prescribed MS treatment from Biogen Idec Inc. Novartis noted that reductions in relapses and MRI measures were observed in these patients.
6/11/2012 2:14 AM ET
Sunday, June 10, 2012
We are about to show you a sensible plan for balanced nutrition developed over a 50-year period of research with hundreds of MS patients. After reading the following, you may wish to print out our Quick Reference and Diet Recording Form to keep handy as you learn the diet. To learn even more, read Dr. Swank's groundbreaking book.
Ft. Worth chiropractor, Dr. Chris Michlin is the only board-certified Atlas Orthogonal adjustment doctor in North Texas, and he uses this technique to treat patients suffering from neck pain, back pain and conditions such as Multiple Sclerosis (MS). A chiropractic Atlas Orthogonal (AO) adjustment realigns the Atlas vertebra at the very base of the skull. According to Dr. Michlin, when this vertebra is improperly aligned, nervous system impulses from the brain to the rest of the body are interrupted, which can cause pain. Dr. Michlin reports that he has helped patients experience relief from conditions such as sciatica, headaches, migraines, fibromyalgia, autism and multiple sclerosis (MS) with this specific type of adjustment.
Approximately 400,000 people in the United States are living with MS. Worldwide, more than 2.1 million people are afflicted with the disease, many with different symptoms and levels of severity.
The disease is unpredictable. While treatments and medication currently on the market can help slow down the attacks, there is no cure.
But the cure for MS just might be sitting right in southeastern Wisconsin's backyard.
Endece LLC, a Mequon-based drug discovery company, recently formed Endece Neural, a subsidiary company focused on neurological drug development. More specifically, Endece Neural is pursing the development of a drug that could help repair and even reverse the damage caused by MS.
Endece's work is getting some attention in the world of MS research.
"We're very excited about the Endece compounds," said Jay Tung, president of drug discovery at the Myelin Repair Foundation in San Francisco.
Endece hopes to collect enough data so the U.S. Food and Drug Administration will accelerate clinical testing enough to have the drug on the market in five to seven years.
"We've already proven that our compound and even our backup compounds work in in vitro (in Petri dish) environments," said James Yarger, chief executive officer of Endece.
Merck Serono to Introduce RebiSlide(TM), the Rebif(R) Multidose Manual Pen-injector for Multiple Sclerosis Treatment
MSWorld, Inc. is covering the 2012 AAN (American Academy of Neurology) Meeting in New Orleans, LA with Dr. Daniel Kantor, President of the Florida Society of Neurology and medical advisor to the MSF. Video updates will be added below in chronological order; the newest updates are at the end. Check back throughout the week for new coverage!
Click here to see the video updates: http://www.msfocus.org/news-details.aspx?newsID=209